ReviewArteriosclerosis, thrombosis, and vascular biology2019
Novel Antiplatelet Therapies for Atherothrombotic Diseases.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 70 citations in OpenAlex.
- Picropodophyllotoxin Suppresses Factor Xa Activity, Platelet Aggregation, and Arterial Thrombosis.Biomolecules · 2026Article
- The crucial role of thromboxane AFrontiers in pharmacology · 2026Review
- [Anticoagulation in the setting of skin surgery].Dermatologie (Heidelberg, Germany) · 2025Review
- Review
- Inflammation resolution-based treatment of atherosclerosis using biomimetic nanocarriers loaded with specialized pro-resolving lipid mediators.Materials today. Bio · 2025Article
- Identification of key genes and diagnostic biomarkers for peripheral atherosclerosis: A multi-omics approach.Medicine · 2025Article
- Role of Thrombosis in Neurodegenerative Diseases: An Intricate Mechanism of Neurovascular Complications.Molecular neurobiology · 2025Review
- Demographic diversity in platelet function and response to antiplatelet therapy.Trends in pharmacological sciences · 2025Review
- Incidence of bleeding during and after two non-surgical periodontal therapy schemes in patients with recent acute coronary syndrome on dual antiplatelet therapy: A pilot study.Journal of clinical and experimental dentistry · 2024Article
- Platelets in Thrombosis and Atherosclerosis: A Double-Edged Sword.The American journal of pathology · 2024Review
- Inhibiting the P2YJACC. Basic to translational science · 2024Article
- Association between 23 drugs and Parkinson's disease: A two-sample Mendelian randomization study.Brain and behavior · 2023Article
- Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia.Iranian journal of public health · 2023Article
- Non-ST Elevation Myocardial Infarction in the Elderly. Antithrombotic Therapy and Beyond.Reviews in cardiovascular medicine · 2023Review
- Antiatherosclerotic Effect and Molecular Mechanism of Salidroside.Reviews in cardiovascular medicine · 2023Review
- P2Y12 Inhibition Suppresses Proinflammatory Platelet-Monocyte Interactions.Thrombosis and haemostasis · 2023Article
- Platelet-Neutrophil Crosstalk in Thrombosis.International journal of molecular sciences · 2023Review
- Meteorin-like/Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: A comprehensive review of preclinical and clinical studies.Frontiers in immunology · 2023Review
- Novel strategies in antithrombotic therapy: targeting thrombosis while preserving hemostasis.Frontiers in cardiovascular medicine · 2023Review
- Transcriptional, epigenetic and metabolic signatures in cardiometabolic syndrome defined by extreme phenotypes.Clinical epigenetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiplatelet therapies are an essential tool to reduce the risk of developing clinically apparent atherothrombotic disease and are a mainstay in the therapy of patients who have established cardiovascular, cerebrovascular, and peripheral artery disease. Strategies to intensify antiplatelet regimens are limited by concomitant increases in clinically significant bleeding. The development of novel antiplatelet therapies targeting additional receptor and signaling pathways, with a focus on maintaining antiplatelet efficacy while preserving hemostasis, holds tremendous potential to improve outcomes among patients with atherothrombotic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.